Clinical Trial Update: Safety and Tolerability of IDO-1 Inhibition in the Prevention of EBV-related Pathology in EBV Negative Kidney Transplant Recipients Receiving an Organ From EBV Positive Donors [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the safety and tolerability of an IDO-1 inhibitor to prevent EBV-related pathology in EBV-negative kidney transplant recipients receivi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epstein-barr Virus Infection

Drugs mentioned

• IDO-1 inhibitor (IDO-1 inhibitor)

Snippet

Sponsor: University Hospital, Basel, Switzerland | Conditions: EBV Infections, Kidney Transplant | Phase 2 | Status: NOT_YET_RECRUITING